Clinicopathologic characteristics associated with long-term survival in advanced epithelial ovarian cancer: an NRG Oncology/Gynecologic Oncology Group ancillary data study

Gynecologic Oncology

Volumn 148, Issue 2, 2018, Pages 275-280

  Hamilton, C A ^a   Miller, A ^b   Casablanca, Y ^a   Horowitz, N S ^c   Rungruang, B ^d   Krivak, T C ^e   Richard, S D ^f   Rodriguez, N ^g   Birrer, M J ^h   Backes, F J ⁱ   Geller, M A ^j   Quinn, M ^k   Goodheart, M J ^l   Mutch, D G ^m   Kavanagh, J J ⁿ   Maxwell, G L ^o   Bookman, M A ^p  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d MEDICAL COLLEGE OF GEORGIA   (United States)

^e WESTERN PENNSYLVANIA HOSPITAL   (United States)

^f DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^g LOMA LINDA UNIVERSITY MEDICAL CENTER   (United States)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

ⁱ THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^j UNIVERSITY OF MINNESOTA   (United States)

^k ROYAL WOMEN'S HOSPITAL   (Australia)

^l UNIVERSITY OF IOWA   (United States)

^m WASHINGTON UNIVERSITY   (United States)

ⁿ UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^o INOVA FAIRFAX HOSPITAL   (United States)

^p Arizona Oncology and US Oncology Research   (United States)

more..

Author keywords

Long term survival; Ovarian cancer

Indexed keywords

CA 125 ANTIGEN; PACLITAXEL; PLATINUM;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BOOTSTRAPPING; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CYTOREDUCTIVE SURGERY; FEMALE; HISTOLOGY; HUMAN; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; OVARY CARCINOMA; OVERALL SURVIVAL; PERITONEUM CANCER; PREDICTION; PRIMARY PERITONEAL CANCER; PRIMARY TUMOR; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; ASCITES; CLINICAL TRIAL; CONTROLLED STUDY; EPIDEMIOLOGY; METABOLISM; MORTALITY; MULTICENTER STUDY; NEOPLASM; OVARY TUMOR; PATHOLOGY; PERITONEUM TUMOR; RANDOMIZED CONTROLLED TRIAL; UNITED STATES;

AGED; ASCITES; CA-125 ANTIGEN; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM, RESIDUAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; ROC CURVE; UNITED STATES;

EID: 85036548798     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2017.11.018     Document Type: Article

References (31)

1. Farley, J.H., Tian, C., Rose, G.S., Brown, C.L., Birrer, M., Maxwell, G.L., Race does not impact outcome for advanced ovarian cancer patients treated with cisplatin/paclitaxel: an analysis of gynecologic oncology group trials. Cancer 115 (2009), 4210–4217.
2. Hamilton, C.A., Miller, A., Miller, C., Krivak, T.C., Farley, J.H., Chernofsky, M.R., et al. The impact of disease distribution on survival in patients with stage III epithelial ovarian cancer cytoreduced to microscopic residual: a gynecologic oncology group study. Gynecol. Oncol. 122 (2011), 521–526.
3. Horowitz, N.S., Miller, A., Rungruang, B., Richard, S.D., Rodriguez, N., Bookman, M.A., et al. Does aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: an analysis of GOG 182. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 33 (2015), 937–943.
4. Rodriguez, N., Miller, A., Richard, S.D., Rungruang, B., Hamilton, C.A., Bookman, M.A., et al. Upper abdominal procedures in advanced stage ovarian or primary peritoneal carcinoma patients with minimal or no gross residual disease: an analysis of gynecologic oncology group (GOG) 182. Gynecol. Oncol. 130 (2013), 487–492.
5. Rungruang, B., Miller, A., Richard, S.D., Hamilton, C.A., Rodriguez, N., Bookman, M.A., et al. Should stage IIIC ovarian cancer be further stratified by intraperitoneal vs. retroperitoneal only disease?: a gynecologic oncology group study. Gynecol. Oncol. 124 (2012), 53–58.
6. Winter WE, 3rd, Maxwell GL, Tian C, Carlson JW, Ozols RF, Rose PG, et al. Prognostic factors for stage III epithelial ovarian cancer: a gynecologic oncology group study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007;25:3621–7.
7. Winter, W.E. 3rd, Maxwell, G.L., Tian, C., Sundborg, M.J., Rose, G.S., Rose, P.G., et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a gynecologic oncology group study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26 (2008), 83–89.
8. Chi, D.S., Liao, J.B., Leon, L.F., Venkatraman, E.S., Hensley, M.L., Bhaskaran, D., et al. Identification of prognostic factors in advanced epithelial ovarian carcinoma. Gynecol. Oncol. 82 (2001), 532–537.
9. Salani, R., Backes, F.J., Fung, M.F., Holschneider, C.H., Parker, L.P., Bristow, R.E., et al. Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. Am. J. Obstet. Gynecol. 204 (2011), 466–478.
10. Sopik, V., Iqbal, J., Rosen, B., Narod, S.A., Why have ovarian cancer mortality rates declined? Part II. Case-fatality. Gynecol. Oncol. 138 (2015), 750–756.
11. Bookman, M.A., Brady, M.F., McGuire, W.P., Harper, P.G., Alberts, D.S., Friedlander, M., et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the gynecologic cancer Intergroup. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27 (2009), 1419–1425.
12. Aletti, G.D., Santillan, A., Eisenhauer, E.L., Hu, J., Aletti, G., Podratz, K.C., et al. A new frontier for quality of care in gynecologic oncology surgery: multi-institutional assessment of short-term outcomes for ovarian cancer using a risk-adjusted model. Gynecol. Oncol. 107 (2007), 99–106.
13. Austin, P.C., Tu, J.V., Bootstrap methods for developing predictive models. Am. Stat. 58 (2004), 131–137.
14. Efron, B., Efron, B., Estimating the error rate of a prediction rule: improvement on cross-validation. J. Am. Stat. Assoc. 78 (1983), 316–331.
15. Harrell, F.E. Jr., Lee, K.L., Mark, D.B., Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat. Med. 15 (1996), 361–387.
16. Akeson, M., Jakobsen, A.M., Zetterqvist, B.M., Holmberg, E., Brannstrom, M., Horvath, G., A population-based 5-year cohort study including all cases of epithelial ovarian cancer in western Sweden: 10-year survival and prognostic factors. International journal of gynecological cancer: official journal of the International Gynecological Cancer Society. 19 (2009), 116–123.
17. Baldwin, L.A., Huang, B., Miller, R.W., Tucker, T., Goodrich, S.T., Podzielinski, I., et al. Ten-year relative survival for epithelial ovarian cancer. Obstet. Gynecol. 120 (2012), 612–618.
18. Cress, R.D., Chen, Y.S., Morris, C.R., Petersen, M., Leiserowitz, G.S., Characteristics of long-term survivors of epithelial ovarian cancer. Obstet. Gynecol. 126 (2015), 491–497.
19. Dao, F., Schlappe, B.A., Tseng, J., Lester, J., Nick, A.M., Lutgendorf, S.K., et al. Characteristics of 10-year survivors of high-grade serous ovarian carcinoma. Gynecol. Oncol. 141 (2016), 260–263.
20. Kotsopoulos, J., Rosen, B., Fan, I., Moody, J., McLaughlin, J.R., Risch, H., et al. Ten-year survival after epithelial ovarian cancer is not associated with BRCA mutation status. Gynecol. Oncol. 140 (2016), 42–47.
21. Milam, M.R., Harrell, R., Bassett, R., Parker, L.P., Metzinger, D.S., Ramirez, P.T., Clinical characteristics of patients with prolonged disease-free survival after primary treatment in advanced ovarian cancer: a brief report. International journal of gynecological cancer: official journal of the International Gynecological Cancer Society. 21 (2011), 475–477.
22. Zorn, K.K., Tian, C., McGuire, W.P., Hoskins, W.J., Markman, M., Muggia, F.M., et al. The prognostic value of pretreatment CA 125 in patients with advanced ovarian carcinoma: a gynecologic oncology group study. Cancer 115 (2009), 1028–1035.
23. Candido-dos-Reis, F.J., Song, H., Goode, E.L., Cunningham, J.M., Fridley, B.L., Larson, M.C., et al. Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 21 (2015), 652–657.
24. Riester, M., Wei, W., Waldron, L., Culhane, A.C., Trippa, L., Oliva, E., et al. Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samples. J. Natl. Cancer Inst., 106, 2014.
25. Berchuck, A., Iversen, E.S., Lancaster, J.M., Pittman, J., Luo, J., Lee, P., et al. Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clinical cancer research : an official journal of the American Association for Cancer Research. 11 (2005), 3686–3696.
26. Barlin, J.N., Jelinic, P., Olvera, N., Bogomolniy, F., Bisogna, M., Dao, F., et al. Validated gene targets associated with curatively treated advanced serous ovarian carcinoma. Gynecol. Oncol. 128 (2013), 512–517.
27. Chan, J.K., Brady, M.F., Penson, R.T., Huang, H., Birrer, M.J., Walker, J.L., et al. Weekly vs every-3-week paclitaxel and carboplatin for ovarian cancer. N. Engl. J. Med. 374 (2016), 738–748.
28. Clamp AR, McNeish I, Dean A, Gallardo D, Weon-Kim J, O'Donnell D, et al. ICON8: a GCIG phase III randomised trial evaluating weekly dose- dense chemotherapy integration in first-line epithelial ovarian/fallopian tube/primary peritoneal carcinoma (EOC) treatment: results of primary progression- free survival (PFS) analysis. Abstract 929O. Presented at the European Society of Medical Oncology 2017 Congress, September 8, 2017, Madrid, Spain.
29. Cancer Genome Atlas Research Network, Integrated genomic analyses of ovarian carcinoma. Nature 474 (2011), 609–615.
30. Konecny, G.E., Wang, C., Hamidi, H., Winterhoff, B., Kalli, K.R., et al. Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer. JNCI J. Natl. Cancer Inst., 106(dju249), 2014.
31. Zhang, H., Liu, T., Zhang, Z., Payne, S.H., Zhang, B., McDermott, J.E., et al. Integrated proteogenomic characterization of human high-grade serous ovarian cancer. Cell 155:3 (2016), 755–765.